Browsing by Author "Mas, Luis"

Now showing 1 - 3 of 3

Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies
(Publmed, 2019) Castañeda, Carlos A.; Castillo, Miluska; Aliaga, Karina; Bernabé, Luis A.; Casavilca, Sandro; Sánchez, Joselyn; Torres-Cabala, Carlos A.; Gómez , Henry L.; Mas, Luis; Dunstan, Jorge; Cotrina, José M; Abugattas, Julio; Chávez, Iván; Ruiz, Eloy; Montenegro, Paola; Rojas, Víctor; Orrego, Enrique; Gálvez-Nino, Marco; Félix , Brayam; Landa-Baella, María P.; Vidaurre, Tatiana; Villa, María R; Zevallos, Rocío; Taxa, Luis; Guerra, Henry; Jorge Luis
Aim: To correlate levels of tumor-infiltrating lymphocytes (TIL) evaluated using the International Immuno-Oncology Biomarker Working Group methodology, and both density of tumor-infiltrating immune cell and clinicopathological features in different malignancies. Methods: 209 pathological samples from gastric cancer, cervical cancer (CC), non-small-lung cancer, cutaneous melanoma (CM) and glioblastoma were tested for TIL in hematoxylin eosin, and density of CD3+, CD4+, CD8+, CD20+, CD68+ and CD163+ cells by digital analysis. Results: TIL levels were higher in invasive margin compartments (IMC). TIL in IMC, intratumoral and stromal compartments predicted survival. CC and gastric cancer had higher TIL in intratumoral; CC and CM had higher TIL in stromal compartment and IMC. CM had the highest density of lymphocyte and macrophage populations. CD20 density was associated with survival in the whole series. Conclusion: Standardized evaluation of TIL levels may provide valuable prognostic information in a spectrum of different malignancies.
Microbiome analysis of 940 lung cancers in neversmokers reveals lack of clinically relevant associations
(Nature, 2025) McElderry, John P.; Zhang, Tongwu; Zhao, Wei; Hoang, Phuc H.; Samuel , Anyaso-Samuel; Sang, Jian; Khandekar, Azhar; Hartman, Caleb; Colón-Mato, Frank J.; Miraftab, Mona; Saha, Monjoy; Lee, Olivia; Sharma, Sunandini; Jones, Kristine M.; Zhu, Bin; Díaz-Gay, Marcos; Mas, Luis; Arrieta Rodriguez, Oscar Gerardo; Edell, Eric S.; Martínez Santamaría, Jacobo; Schabath, Matthew B.; Yendamur, Sai; Manczuk, Marta; Lissowska, Jolanta; Świątkowska, Beata; Mukeria, Anush; Shangina, Oxana; Zaridze, David; Holcatova, Ivana; Janout, Vladimir; Mates, Dana; Ognjanovic, Simona; Savic, Milan; Kontic, Milica; Bossé, Yohan; Gould Rothberg, Bonnie E.; Christiani, David C.; Gaborieau, Valerie; Brennan, Paul; Liu, Geoffrey; Hofman, Paul; Pik Wong, Maria; Chung Leung, Kin; Chen, Chih-Yi; Hsiung, Chao Agnes; Rothman, Nathaniel; Leduc, Charles; Baine, Marina K.; Travis, William D.; Sholl, Lynette M.; Joubert, Philippe; Homer, Robert; Yang, Soo-Ryum; Lan, Qing; Nowak, Martin A.; Wedge, David C.; Alexandrov, Ludmil B.; Chanock, Stephen J.; Vogtmann, Emily; Abnet, Christian C.; Shi, Jianxin; Landi, Maria Teresa
In spite of the growing interest in the microbiome in human cancer, there are currently only small-scale lung cancer microbiome studies conducted directly on tissue. As part of the Sherlock-Lung study, we studied the microbiomes of 940 lung cancers (4,090 samples) in never smokers (LCINS) directly from lung tissue using three data types: 16S rRNA gene sequencing (16S), whole-genome sequencing (WGS) with paired blood, and RNA-seq. We observe very low biomass and few microbiome associations in LCINS using 16S and WGS tissue. Using RNA-seq, we observe more total microbial reads, and decreased relative abundance of several commensal bacteria at the genus and species levels in tumors relative to paired normal lung tissue. Among all datasets, we see no consistent associations between the lung tissue microbiome, or circulating bacterial DNA, and any available demographic and clinical features, including age, sex, genetic ancestry, second-hand tobacco smoking exposure, LCINS histology, stage, and overall survival. We also observe no microbiome associations with any human genomic alterations within the same samples. Every null result should be interpreted with caution given the possibility of future methodological breakthroughs. However, all together, using multiple data types in nearly 1,000 patients, we find no substantive role for the lung cancer microbiome in treatment-naïve LCINS.
Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
(Instituto Nacional de Salud, 2018) Alcarraz Molina, Cindy; Muñiz, Johana; Mas, Luis; Olivera, Mivael; Morante, Zaida
Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with post-surgery levels of carcinoembryonic antigen 125 > 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival.